title: Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
abstract: BACKGROUND
  Clinical experience with mycophenolate mofetil (MMF) in glomerulonephritis still remains limited.
  
  
  METHODS
  In order to assess the experience of one center with the efficacy and tolerability of MMF in patients with glomerulonephritis, we performed a retrospective 6-year analysis of 68 patients treated by MMF for glomerular disease, mainly anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV: n=34) and systemic lupus erythematosus and lupus nephritis (SLE: n=24). Indications were maintenance treatment in 40% of patients, induction treatment in patients not tolerating cyclophosphamide in 27%, and disease relapse in 33%. Mean treatment duration was 11.5 months.
  
  
  RESULTS
  Efficacy endpoints were serum creatinine, urinary protein excretion, and steroid dose. In AAV patients, MMF was associated with significant improvement in 18%, partial improvement in 26%, stabilization in 29%, and disease progression in 12%; adverse event dropouts totalled 15%. In SLE, the respective figures were 30, 22, 9, and 22%, with 17% adverse event dropouts. The most frequent side effects were gastrointestinal events (n=7) and infections (n=3). None was life-threatening and there were no deaths.
  
  
  CONCLUSIONS
  MMF, in the relatively low doses used, was safe and effective, stabilizing or improving AAV in 73% of patients and SLE in 61%. Further prospective randomized controlled trials with MMF in renal vasculitis and lupus nephritis are clearly warranted.
authors: Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. mkzderova@centrum.cz
authors: Marketa
authors: M
authors: Kazderova
authors: Eva
authors: E
authors: Jancova
authors: Romana
authors: R
authors: Rysava
authors: Miroslav
authors: M
authors: Merta
authors: Vladimir
authors: V
authors: Tesar
mesh_terms: D001323:Autoantibodies / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008181:Lupus Nephritis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009504:Neutrophils / Q000276:immunology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D001323:Autoantibodies; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid